Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: A preclinical evaluation

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8112-8122

  Emtage, Peter C R ^b   Lo, Agnes S Y ^b   Gomes, Erica M ^a   Liu, David L ^b   Gonzalo Daganzo, Rosa M ^b   Junghans, Richard P ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CD28 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; UNCLASSIFIED DRUG; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; SECRETION;

ANIMALS; ANTIGENS, CD28; APOPTOSIS; CARCINOEMBRYONIC ANTIGEN; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 58149331194     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4910     Document Type: Article

References (52)

1. Rosenberg SA. Principles and applications of biologic therapy. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Lippincott; 1993. p. 293-324.
2. Ma QZ, Gonzalo-Daganzo R, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. In: Giaccone R, Schlinsky R, Sondel P, editors. Cancer chemotherapy and biological response modifiers - annual 20. Oxford: Elsevier Science; 2002. p. 319-45.
3. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
4. Restifo NP, Marincola FM, Kawakami Y,Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional β2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88:100-8.
5. + cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1995;92:11990-2.
6. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007;7:532-42.
7. Noel PJ, Boise LH, Green JM, Thompson CB. CD28 costimulation prevents cell death during primary T cell activation. J Immunol 1996;157:636-42.
8. Radvanyi LG, Shi Y,Vaziri H, et al. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 1996;156:1788-98.
9. Nolan KF, Yun CO, Akamatsu Y, et al. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999;5:3928-41.
10. Junghans RP, Safar M, Huberman MS, et al. Preclinical and phase I data of anti-CEA "designer T cell" therapy for cancer: a new immunotherapeutic modality. Proc Am Soc Clin Oncol 2001;19:A1063.
11. Beecham EJ, Ma QZ, Ripley R, Junghans RP. Coupling of CD28 co-stimulation to IgTCR molecules: dynamics of T cell proliferation and death. J Immunother 2000;23:631-42.
12. Thomas P, Gangopadhyay A, Steele GD, et al. The effect of transfection of the CEA gene on the metastatic behavior of the human colorectal cancer cell line MIP-101. Cancer Lett 1995;92:59-66.
13. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935-45s.
14. Beaudoin EL, Bais AJ, Junghans RP. Sorting vector producer cells for high transgene expression increases retroviral titer. J Virol Methods 2008;148:253-9.
15. Emtage PCR, Clarke D, Gonzalo R, Junghans RP. Generating potentTh1/Tc1 T cell adoptive immunotherapy doses using human IL-12: harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity. J Immunother 2002;26:97-106.
16. Alvarez-Vallina L, Harkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 1996;26:2304-9.
17. Finney HM, Lawson ADG, Bebbington CR, Weir ANC. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998;161:2791-7.
18. Krause A, Guo H, Latouche J, Tan C, Chueng NV, Sadelain M. Antigen-dependent CD28 signaling selectivelyenhances survival and proliferation in genetically modified activated human primaryT lymphocytes. J Exp Med 1998;188:619-26.
19. Beecham EJ, Ortiz-Pujols S, Junghans RP. Dynamics of tumor cell killing by human T lymphocytes armed with an anti-CEA chimeric immunoglobulin-T cell receptor. J Immunother 2000;23:332-43.
20. + helper T cells induces potent primary and secondary tumor rejection. Blood 2005;106:2995-3003.
21. Romagnani S, Kapsenberg M, Radbruch A, Adorini L. Th1 and Th2 cells. Res Immunol 1998;149:871-3.
22. Lotze MT, Frana LW, Sharrow SO, Robb RJ,Rosenberg SA. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 1985;134:157-66.
23. Noel PJ, Boise LH, Thompson CB. Regulation of T cell activation by CD28 and CTLA4. Adv Exp Med Biol 1996;406:209-17.
24. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999;59:1693-700s.
25. Schwartz MK. Cancer markers. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles andpractice of oncology. Lippincott;1993. p. 531-42.
26. Boucher D, Cournoyer D, Stanners CP, Fuks A. Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. Cancer Res1989;49:847-52.
27. Hansen H, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization of second generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993;71:3478-85.
28. Scheinberg DA, Sgouros G, Junghans RP. Antibody-based immunotherapies for cancer. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy. 4th ed. Philadelphia: Lippincott; 2006. p. 850-90.
29. Deeks SG,Wagner B, Anton PA, et al. AphaseII randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002;5:788-97.
30. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-15.
31. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolyticT lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15:825-33.
32. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologousT-lym-phocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24:e20-2.
33. Sprent J. Stimulating naive T cells. J Immunol 1999;163:4629-36.
34. Hodge JW, Sabzevari H,Yafal AG, Gritz L, Lorenz MGO, Schlom J. A triad of costimulatory molecules synergize to amplify T cell activation. Cancer Res 1999;59:5800-7.
35. Boise LH, Minn AJ, Noel PJ, et al. CD28 co-stimulation can promote T cell survival by enhancing the expression of Bcl-xl. Immunity 1995;3:87-98.
36. Kirchhoff S, Muller WW, Li-Weber M, Krammer PH. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur J Immunol 2000;30:2765-74.
37. + T cell activation throughcaspase-8-dependent NF-κB activation. J Immunol 2005;174:5270-8.
38. Krueger A, Fas SC, Baumann S, Krammer PH. The role ofCD95 in the regulation of peripheral T-cell apo-ptosis. Immunol Rev 2003;193:58-69.
39. Hombach A,Wieczarkowiecz A, Marquardt T, et al. Tumor-specificTcell activation by recombinant immu-noreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J Immunol 2001;167: 6123-31. Erratum in: J Immunol 2004;173:695.
40. Giacomini P, Fisher PB, Duigou GJ, Gambari R, Natali PG. Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon. Anticancer Res 1988;8:1153-61.
41. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
42. Xiao BG, Zhang GX, Ma CG, Link H. Transforming growth factor-β1 (TGF-β1)-mediated inhibition of glial cell proliferation and down-regulation of intercellular adhesion molecule-1 (ICAM-1) are interrupted by interferon-γ (IFN-γ). Clin Exp Immunol 1996;103:475-81.
43. Strober W, Kelsall B, Fuss I, et al. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today1997;18:61-4.
44. Haynes NM, Trapani JA, Teng MW, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002;100:3155-63.
45. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006;20:1819-28.
46. + T cells in an antitumor cell attack. Cancer Res 2007;67:2265-73.
47. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL.T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005;174:7853-8.
48. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR ζ chain.J Immunol 2004;172:104-13.
49. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. HumanT-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol 2002;20:70-5.
50. Moeller M, Haynes NM,Trapani JA, et al. Afunctional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 2004;11:371-9.
51. Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma through chimeric anti-GD3 immunoglobulin-T cell receptors (IgTCR). Neoplasia 2000;2:449-59.
52. Renner C, Jung W, Sahin U, et al. Cure of xeno-grafted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994;264:833-5.